Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s): RKVTF

Healthcare Biotechnology

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.

TSXV:RKV - Post by User

Rakovina Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(2269)
•••

Post by Betteryear2on Apr 12, 2022 9:07am

210 Views

Post# 34596347

Rakovina Therapeutics Presents Preclinical Data Supporting

VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) targeting technologies, is pleased to announce the Company’s poster presentation at the AACR Annual Meeting.

Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting

<< Previous

Bullboard Posts

Next >>

Nuclear power, uranium, and global energy trends